Management of Hyperkalemia (Potassium 5.8 mmol/L)
For a 60-year-old woman with a potassium level of 5.8 mmol/L, immediately obtain an ECG and assess for symptoms; if ECG changes or symptoms are present, initiate acute treatment with IV calcium gluconate followed by insulin/glucose and nebulized salbutamol, but if asymptomatic with normal ECG, focus on identifying and correcting reversible causes while considering potassium binders to normalize levels rather than discontinuing essential medications like RAASi. 1
Initial Assessment
First, determine if this is acute or chronic hyperkalemia:
- Check for ECG abnormalities (peaked T waves, prolonged QRS, though these may be absent even in severe cases) 1
- Assess for symptoms: muscle weakness, paralysis, cardiac arrhythmias 2
- Rule out pseudohyperkalemia (hemolysis, fist clenching during blood draw, delayed processing) 1
- Review medication list and recent changes
- Assess kidney function, volume status, and acid-base balance 3
Critical point: A potassium of 5.8 mmol/L falls into the moderate hyperkalemia range (5.5-6.0 mmol/L is widely accepted as the threshold requiring intervention), but ECG changes and symptoms determine urgency, not just the number 1.
Acute Management (If ECG Changes or Symptoms Present)
If ECG abnormalities or symptoms exist, treat immediately:
IV calcium gluconate 10 mL of 10% - stabilizes cardiac membrane within 1-3 minutes; repeat in 5-10 minutes if no effect 1
Shift potassium intracellularly (within 30-60 minutes):
Sodium bicarbonate IV - only if metabolic acidosis present 1
Loop diuretics - if patient has preserved kidney function and is hypervolemic 1
Hemodialysis - if oliguria, ESRD, or resistant hyperkalemia 1
Subacute/Chronic Management (If No ECG Changes or Symptoms)
The 2025 European Heart Journal guidelines emphasize that the primary goal is normalizing potassium levels while maintaining life-saving therapies 4:
Step 1: Identify and Correct Reversible Causes
- Review ALL medications (NSAIDs, potassium-sparing diuretics, trimethoprim, heparin)
- Assess for acute kidney injury or worsening CKD
- Check for metabolic acidosis
- Evaluate for hypoaldosteronism
- Do NOT automatically discontinue RAASi - this increases mortality risk 1
Step 2: Initiate Potassium Binders
Newer potassium binders are preferred over older agents 4, 1:
- Patiromer or sodium zirconium cyclosilicate (SZC) - these are guideline-recommended and have robust clinical trial data supporting safety and efficacy 1, 2, 5
- Avoid sodium polystyrene sulfonate (SPS) - associated with intestinal ischemia, colonic necrosis, and serious GI adverse events; limited efficacy data 1, 2
Key advantage: Potassium binders allow continuation and optimization of RAASi therapy, which improves cardiovascular and renal outcomes 4, 1
Step 3: Optimize Diuretic Therapy
- Loop or thiazide diuretics if patient has adequate kidney function and is not volume depleted 1, 3
- Promotes urinary potassium excretion
Step 4: Dietary Counseling (Nuanced Approach)
Important caveat: The evidence linking dietary potassium restriction to serum potassium levels is limited 1. A potassium-rich diet has cardiovascular benefits, and strict restriction is difficult to maintain 1.
- Focus on reducing non-plant sources of potassium rather than blanket restriction 6
- Avoid overly restrictive diets that compromise nutrition
Monitoring Strategy
After initiating treatment:
- Recheck potassium within 7-10 days after starting or adjusting RAASi doses 1
- More frequent monitoring in high-risk patients (CKD, diabetes, heart failure, history of hyperkalemia) 1
- Once stabilized on potassium binder, additional monitoring beyond routine comorbidity management is not necessary 4
Critical Pitfalls to Avoid
Do NOT discontinue RAASi reflexively - discontinuation increases mortality and cardiovascular events in patients with CKD, heart failure, or diabetes 1. Treat the hyperkalemia instead.
Do NOT rely solely on ECG - ECG changes are highly variable and may be absent even with severe hyperkalemia 1
Do NOT use SPS as first-line - serious GI complications and poor evidence base 1, 2
Do NOT assume dietary restriction alone will suffice - evidence is weak, and overly restrictive diets harm quality of life 1
Recognize this as likely a chronic/recurrent condition - unless the cause is reversible, treatment will be indefinite 4
Long-Term Strategy
The 2025 European guidelines emphasize that reducing recurrence risk should be standard practice 4:
- Maintain potassium binder therapy indefinitely if cause cannot be reversed 4
- Continue RAASi at optimal doses 4, 1
- Establish coordinated care across specialties (cardiology, nephrology, primary care) 1, 3
- Patient education on avoiding excessive dietary potassium and recognizing triggers (fever, diarrhea) 7, 8